NCT03701607

Effect of Chemotherapy on PD-L1 in NSCLC

Effect of Platinum-based Chemotherapy on PD-L1 Expression in Patients With Advanced Non-small Cell Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Baodong Qin · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving chemotherapy in advanced NSCLC patients.

Conditions

• Chemotherapy
• Immunotherapy
• PD-L1

Interventions

Type	Name	Description
OTHER	PD-L1 group	PD-L1 expression is evaluated using immunohistochemical assay

Timeline

• Start date: 2018-09-01
• Primary completion: 2019-02-28
• Completion: 2019-08-31
• First posted: 2018-10-10
• Last updated: 2018-10-10

Locations

1 site across 1 country: China